<DOC>
	<DOCNO>NCT00981487</DOCNO>
	<brief_summary>This study assess effect food single dose Ondansetron take meal empty stomach .</brief_summary>
	<brief_title>Bioavailability Study Anti Nausea Medication With Without Food ( EUR-1025 )</brief_title>
	<detailed_description>The objective study assess effect food pharmacokinetics single 24 mg dose Ondansetron administer novel modified-release capsule formulation feed fasting condition .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>male female volunteer , non exsmokers , least 21 year age old 55 year , body mass index target least 18.5 less 30 kg/m2 healthy , acceptable normal lab test , negative HIV , Hepatitis B C , negative ethyl alcohol drug screen , normal 12 lead ECG , AND negative human chorionic gonadotropin ( hCG ) female . know hypersensitivity ondansetron relate product , presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect , history significant gastrointestinal , liver kidney disease , presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric endocrine , immunologic dermatologic disease , suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease , presence significant heart disease disorder discover screen ECG , females find positive serum pregnancy test screen nursing , females childbearing potential refuse use acceptable contraceptive regimen screen visit throughout study , maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 2 unit alcohol per day , intake excessive alcohol , acute chronic ) , clinically significant illness previous 28 day day 1 study , use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day day 1 study , volunteer take Investigational Product ( another clinical trial ) donate 50 ml blood previous 28 day day 1 study , poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician , donation 500 ml blood ( Canadian Blood Services , HemaQuebec , clinical study ) previous 56 day day 1 study , positive urine screen drug abuse , history tuberculosis and/or prophylaxis tuberculosis , OR positive result HIV , HBsAg , antiHCV test . subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>